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Abstract 
Objective: To ascertain estimates of adult patients, recorded as lost to follow-up (LTFU) within an-
tiretroviral treatment (ART) programmes, who have self-transferred care, died or truly stopped ART 
in low- and middle-income countries.  
 
Methods: PubMed, EMBASE, Web of Science, Science Direct, LILACS, IndMed and AIM databases 
(2003-2013) and IAS/AIDS conference abstracts (2011-2013) were searched for tracing studies re-
porting the proportion of traced patients found to have self-transferred, died or stopped ART. These 
estimates were then combined using random-effects meta-analysis. Risk of bias was assessed 
through subgroup and sensitivity analyses.  
 
Results: 28 studies were eligible for inclusion, reporting true outcomes for 10,806 traced patients at-
tending approximately 258 ART facilities. None were from outside sub-Saharan Africa. 23 studies re-
ported 4.5-54.4% traced LTFU patients self-transferring care, providing a pooled estimate of 18.6% 
(95% CI 15.8-22.0%). A significant positive association was found between rates of self-transfer and 
LTFU in the ART cohort. The pooled estimates for unreported deaths was 38.8% (95% CI 30.8-46.8%; 
27 studies), and 28.6% (95% CI 21.9-36.0%; 20 studies) for patients stopping ART. A significant de-
crease in unreported deaths from 50.0% (95% CI 41.5-58.4%) to 30.0% (95% CI 21.1-38.9%) was 
found comparing study periods before and after 31/12/2007.  
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Conclusions: Substantial unaccounted for transfers and deaths among patients LTFU confirms that 
retention and mortality is underestimated where the true outcomes of LTFU patients are not ascer-
tained. 
 
Keywords: HIV; antiretroviral therapy; lost to follow-up; mortality; continuity of care; systematic re-
view 
 
Introduction 
Retention in care is a key measure of the success of HIV treatment programmes. In sub-Saharan Afri-
ca, around a third of patients are reported as lost to follow-up (LTFU) within three years of initiating 
antiretroviral therapy (ART) (Fox and Rosen 2010).  LTFU is a general term for largely unknown out-
comes of patients that have not returned to a particular clinic to collect their next supply of ART.  
True outcomes for such patients can be divided into 3 categories: patients who have self-transferred 
to another facility, those who have died, and those who have discontinued treatment (McMahon et 
al. 2013, Brinkhof et al. 2009).  
 
With expanding ART coverage, increased decentralisation of ART services to primary 
healthcare and growing patient confidence to select where to access ART, patients are increasingly 
transferring between ART providing facilities (Geng et al. 2010b, Nglazi et al. 2013).  These transfers 
may be formal or undocumented, the latter are referred to in this paper as ‘self-transfers’.  Self-
transfers may occur for both health system and personal reasons including: facility congestion and 
perceptions of depersonalised services, permanent or temporary relocation, lack of patient aware-
ness of transferring processes, and ease of transferring without documentation due to increasing 
numbers of ART providers (Wubshet et al. 2013, Mben et al. 2012, Nglazi et al. 2013).  Failure to ac-
count for patients self-transferring care can result in underestimated retention in ART care.  Accu-
rate retention outcomes are essential to ensure appropriate forecasting, costing and supply chain 
management of human resource requirements, drugs and laboratory investigations, and to measure 
the success of ART scale-up (Tweya et al. 2013).   
 
True outcomes of patients classified as LTFU are generally determined by either active trac-
ing or data linkage to national death registries (Geng et al. 2010b, Van Cutsem et al. 2011). While 
some ART programmes in low- and middle-income countries conduct tracing routinely, this is not 
generally done due to resource constraints. More commonly, tracing studies have been conducted 
at a specific time point on either all or a sample of patents who are LTFU, to improve classification of 
unknown outcomes and link patients back into care (McMahon et al. 2013, Rosen and Ketlhapile 
2010,  Geng et al. 2010a).   
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Two previous reviews have highlighted substantial numbers of self-transfers amongst LTFU 
patients. The first, a systematic review, reported self-transfer rates of 12-54% amongst patients 
found alive (Brinkhof et al. 2009). The second, a narrative review, estimated a crude unweighted 
median self-transfer rate of 48.5% amongst those reported in 14 cited studies as LTFU (Geng et al. 
2010b).  
 
We systematically reviewed outcomes reported in tracing studies of adult ART patients who 
are reported as LTFU in low- and middle-income countries (LMICs) to provide an updated assess-
ment of the extent to which self-transfers – a positive outcome - contributed to the overall propor-
tion of people considered to be lost to care. 
 
Methods 
Search strategy 
We followed the approach set out in the Preferred Reporting Items for Systematic reviews and Me-
ta-Analyses guidelines (Moher et al. 2009).  Using a predetermined study protocol (see Web Appen-
dix), we searched seven databases – Pubmed, EMBASE, Science Direct, Web of Science, Latin Ameri-
can and Caribbean Health Sciences Literature (LILACS), Indian Medlars Centre (IndMed) and African 
Index Medicus (AIM) – from 1 January 2003 to 31 December 2013 to identify observational cohort 
studies reporting true outcomes of patients LTFU in LMICs. Randomised and non-randomized con-
trolled trials were excluded as these cannot provide representative estimates of LTFU rates in pro-
gramme settings. Highly sensitive search strategies were developed for each database with the assis-
tance of a professional librarian (Umscheid 2013), as detailed in the study protocol.   
 
We also searched the conference abstract sites of all conferences of the International AIDS 
Society from 2011-2013 to enable inclusion of data from studies not published to date. All systemat-
ic reviews and editorial articles identified, and selected studies’ reference lists were manually 
searched to identify further studies for eligibility assessment (Moher et al. 2009, Liberati et al. 2009).   
 
Study selection and data extraction 
Studies reporting on HIV patients on ART in LMICs with LTFU as an outcome were included provided 
true outcomes of all or a subset of LTFU patients were ascertained by tracing.  We excluded studies 
that reported on infant, paediatric, adolescent or prevention-of-mother-to-child transmission 
(PMTCT) specific cohorts, as well as studies that reported LTFU among patients prior to initiating 
ART, unless ART outcomes were also reported and able to be disaggregated.   
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Where more than one study reported on the same cohort, the study reporting on the largest 
cohort was included. Where identical cohorts were published, the study with the latest publication 
date was included to obtain the most updated data. Study eligibility assessment was done by one 
reviewer (LW) and confirmed by a second reviewer who assessed 10% of titles and 100% of full arti-
cles for eligibility (NF); any discrepancies were resolved by a third reviewer (JSW). Data were ex-
tracted by one reviewer (LW) and verified by a second reviewer (OA) using a standardized data ex-
traction form.  Information was extracted on study and programme characteristics (study period, lo-
cation, and country of study, urban or rural setting and provider type); cohort characteristics (num-
ber of adult patients initiated on ART; definition of LTFU; number of reported deaths or formal trans-
fers and number meeting the LTFU definition) and outcomes (number of patients in the tracing 
study, number traced, tracing methods, reasons for failed tracing, and outcomes).  Where discrep-
ancies arose, these were resolved in consultation with a third reviewer (NF).   
 
To provide consistency across studies, the following three standardised approaches were 
taken.  Firstly, patients who could not be traced due to incorrect contact details or living outside the 
tracing area were included in the tracing study cohort. Secondly, study participants identified 
through tracing efforts to have relocated were considered untraceable (their true outcomes remain-
ing unknown).  Lastly, study participants reported to be obtaining ART privately were included as 
self-transfers.   
 
Assessment of heterogeneity and risk of bias in included studies and across studies  
Selected studies were assessed for study level and outcome-level risk of bias using the following cri-
teria, which if not met or uncertain whether met, indicated a risk of bias:  published in peer re-
viewed journal; prospective study design; all or a random sample of LTFU patients included; more 
than two thirds of study participants traced; disaggregated adult data reported; and method of trac-
ing included home visits where the patient could not be reached by telephone. Where the study did 
not trace all or a random sample of patients, had limited tracing success or only traced by telephone, 
there is a risk that true outcome results of the study may be affected by selection bias.  Where the 
study aggregated tracing outcomes for adults and children, there was an increased risk that LTFU, 
tracing success rates and tracing outcomes may be biased by the paediatric cohort.  Risk of bias cat-
egories were not scored for purposes of the meta-analyses due to the inherent subjectivity in such 
approaches, but the potential influence of various study characteristics was explored through sub-
group or sensitivity analysis (Jüni et al. 1999, Umscheid 2013).   
 
The risk of bias assessment (Web Appendix) was used as part of the overall assessment of 
the quality of the evidence. 
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Statistical analysis and data synthesis 
This study’s primary outcome is the percentage of traced LTFU patients determined to have self-
transferred care in each included study. The secondary outcomes are the percentage determined to 
have died and stopped ART. Point estimates and 95% confidence intervals (CI) were calculated for 
individual studies and combined using random-effects meta-analysis on the arcsin scale, then back 
transformed prior to pooling (Freeman 1950, Miller 1978). Combined estimates were transformed 
back to percentages.  Heterogeneity between included studies was assessed visually by forest plot 
and statistically by estimating the τ2 statistic (Higgins et al. 2003, Rücker et al. 2008).     
 
The association between the primary outcome and the proportion LTFU in the ART cohort 
was explored using univariate random effects meta-regression. In addition, subgroup analyses were 
undertaken to determine the potential influence risk of bias covariates, study period and LTFU peri-
od on the primary and secondary outcomes.  Study period stratification was grouped into those end-
ing before and after 31/12/2007. 2008 was the year in which the WHO recommended decentraliza-
tion of ART services (WHO 2008), and by which time a number of high burden HIV countries had al-
ready started implementing decentralization, including Malawi, Mozambique, South Africa and Swa-
ziland (Lowrance et al. 2008, Decroo et al. 2011, Boulle et al. 2008, van Schalkwyk et al. 2013). LTFU 
period was stratified into less or more than 3 months from the patient’s last visit due to most studies 
defining LTFU for tracing purposes as less than 6 months and approximately half defining such peri-
od as less than 3 months. Sensitivity analyses were carried out to determine the potential influence 
of studies that combined outcomes for adults and children, and studies that reported outcomes on 
an incomplete or non-random sample of patients.   
Analyses were done in STATA Version 13(StataCorp 2013).  
 
Results 
Study selection and characteristics of inclusions 
From the initial search, 2597 published items were retrieved and another 364 items identified from 
other sources, including 3 from reference lists and 361 from conferences.  Of these, 36 met the eligi-
bility criteria, including 29 full text journal articles and 7 abstracts from conferences (Figure 1). 8 
studies reported on the same cohort of traced patients. This systematic review therefore included 28 
studies that described true outcomes of 10,806 LTFU patients attending approximately 258 ART 
providing facilities. 
 A total of 12 countries were represented, all in sub-Saharan Africa, with a third (9/28) from 
South Africa. 12 study cohorts were drawn from urban areas, 6 from rural, and 10 included both ur-
ban and rural cohorts.  The vast majority of studies were conducted in public sector facilities with 
only 2 from the private sector, one of which was a workplace programme (Dahab et al. 2011).  15 
studies were conducted in adult cohorts, 5 reported data for adults and children, and the remainder 
did not specify. Study characteristics are summarized in Table 1. 
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Cohort size varied from 352 (Kato et al. 2013) to 47,858 (Toure et al. 2012) patients initiated 
on ART. These cohorts were drawn from 1 to 138 healthcare facilities.  The percentage of patients 
classified as LTFU for tracing purposes ranged from 2.7% (Maskew et al. 2007) to 55.4% (Alamo et al. 
2012). Most tracing studies attempted to trace all LTFU patients, with 3 studies tracing a random 
sample of patients, 2 studies tracing a non-random sample (Omotoso 2011, Krebs et al. 2008) and 1 
study only reporting on the number of patients traced (Mben et al. 2012).  
 
There was extensive variability in LTFU definitions applied for the purposes of determining 
the study cohort for tracing. The period for which a patient was missing before they were considered 
LTFU ranged from 1 week to 6 months. This period also varied from either time since last visit (6 
studies) or time since missed appointment (16 studies).  2 studies provided no definition for LTFU. 
Reporting of tracing methods was also heterogeneous and not well described in a number of studies; 
5 studies only attempted to contact patients by telephone, 21 studies attempted to trace by home 
visit either after failed telephone contact or not, and 2 studies only reported the number of tracing 
attempts not the method. 
Overall, the quality of evidence contributing to the assessment of true outcomes of traced 
LTFU patients was considered to be low to moderate, mainly due to the risk of bias within studies, 
inconsistency in results, and imprecision in estimates.  
True outcomes of LTFU patients traced 
A total of 10,806 patients were traced, representing 16.6-96.3% of the overall tracing study cohort.  
Table 2 summarises the number of patients traced and their true outcomes. Figures 2 - 4 summariz-
es the percentage of traced patients who self-transferred, died and stopped ART in each study re-
porting such outcomes, including confidence intervals (CI) for the point estimates.  The combined 
self-transfer summary estimate from random effects meta-analysis is 18.6% (95% CI 15.8-22.0%). 
There was extensive heterogeneity (τ2 0.08, p <0.000).  The combined summary estimate from ran-
dom effects meta-analysis for death was 38.8% (95% CI 30.8-46.8%) and patients stopping ART was 
28.6% (95% CI 21.9-36.0%).    
In the random effects meta-regression (Figure 5), there was a statistically significant positive 
association between the proportion who self-transferred amongst those traced and the proportion 
LTFU in the overall ART cohort (β-coefficient 0.5, 95% CI 0-0.9).  
 
Subgroup and sensitivity analysis and investigation of heterogeneity 
Published studies reported a significantly higher percentage of self-transfers (21.8%, 95%CI 16.2-
27.3%) than conference abstracts (8.0%, 95%CI 6.3-9.7%) (p=0.03). Study period and tracing method 
significantly influenced the percentage of unreported deaths. The percentage of deaths decreased 
from 50.0% (95% CI 41.5-58.4) to 30.0% (95% CI 21.1-38.9%%) in study periods ending after 
31/12/2007, with a lower percentage of deaths ascertained where tracing was only attempted by 
telephone (21.8%, 95%CI 13.9-29.6% v 42.6%, 95%CI 31.8-53.5%). 
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A tendency towards a lower self-transfer percentage was found where study periods ended 
before versus after 31/12/2007 (16.6%, 95% CI 12.5-20.8% v 20.3%, 95% CI 15.7-25.0%), and where 
fewer versus two-thirds or more study participants were traced (16.0%, 95% CI 12.3-19.7% v 23.1%, 
95% CI 15.0-31.2%). 
 
In sensitivity analysis, exclusion of studies aggregating outcomes for adults and children, or 
not specifying population age, led to a non-statistically significant increase in percentage of self-
transfers (23.8%, 95%CI 15.8-31.8%). Exclusion of non-random tracing cohorts made no difference.  
There was also no statistically significant difference to the summary estimates of deaths or stopping 
ART when performing the same sensitivity analyses.   
 
Discussion  
This review found that almost one in five ART patients initially reported as LTFU had self-transferred 
and was retained in ART care. This finding implies that retention in ART care in sub-Saharan Africa is 
underestimated due to unknown outcomes of LTFU patients. There is evidence that self-transfers 
have increased after the scale up of ART coverage and decentralization. The significant positive asso-
ciation found in our study between self-transfer and LTFU proportions means that programmes with 
higher LTFU rates can expect higher self-transfer rates and a greater underestimation of retention. 
Two explanations may provide insight into this finding. Firstly, LTFU rates have been found to posi-
tively correlate with ART programme size (Boulle et al. 2010) and programme expansion rates 
(Grimsrud et al. 2014) and it is possible that as cohort sizes expand, patients are more likely to self-
transfer. Secondly, higher LTFU rates have been found in centralized than primary healthcare facili-
ties (Fatti et al. 2010), indicating that patients may self-transfer as the number of facilities offering 
ART increases and patients are able to access facilities closer to home. 
 
This review also provides an updated summary estimate of 38.8% (95% CI 30.8-46.8%) for 
mortality among ART patients LTFU, compared with 42% (95% CI 34-50%) found previously (Brinkhof 
et al. 2009).  Importantly, we found a significant decrease from 50% (95% CI 42-58%) to 30% (95% CI 
21-39%) in deaths identified by tracing studies with study periods ending after 31/12/2007.  This 
may be attributable to growing access to ART (Grimsrud et al. 2014) and the reduction in the risk of 
death associated with patients in LMICs initiating ART with higher CD4 counts (Gupta et al. 2011, 
Avila et al. 2014).  
 
This review differs in several ways from the previous systematic review of outcomes among 
patients LTFU published in 2009 (Brinkhof et al. 2009). We excluded studies reporting pre-ART out-
comes; we report the proportion of self-transfers as a percentage of those traced (not of those 
found alive upon tracing); and we include data up to the end of 2013, which allowed for the inclu-
sion of outcomes for more than double the number of traced patients.   
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There are inherent limitations to systematic reviews, especially those summarising results 
from research conducted in routine care settings. This review has a number of limitations. Firstly, 
systematic reviews of routine programme outcomes are by definition prone to publication bias, as 
evidenced by the fact that no studies were identified that reported outcomes from LMICs outside of 
sub-Saharan Africa.  It does not appear, however, that publication bias has favoured the reporting of 
positive findings as there was substantial variability between studies, including a number of studies 
reporting relatively high rates of negative outcomes. Secondly, heterogeneous definitions of LTFU 
for tracing purposes may mean that studies with shorter intervals were likely to have the number of 
LTFU patients exaggerated by treatment interrupters (i.e. patients who return to care after a short 
period of absenteeism) (Shepherd et al. 2013), thereby increasing the size of the tracing study co-
horts.  While the number of patients who self-transferred or died should not change, our LTFU defi-
nition may have influenced self-transfer and death rates. Thirdly, the lower self-transfer rate found 
when limiting the meta-analysis to studies with poor tracing success suggests that large numbers of 
untraceable patients may underestimate the self-transfer rate (this was not the case for the per-
centage deaths). Fourthly, it may not be appropriate to assume that the true outcomes of untracea-
ble patients are comparable to those who were traced. Patients with lower socio-economic status 
are more likely to stop ART than self-transfer (Marson et al. 2013), and access to a telephone (which 
facilitates tracing) may be an indicator of better socioeconomic status, which in turn may influence 
survival.  Patients who relocate are also less likely to be traced.  Due to the risk that true outcome 
results of tracing studies may be affected by selection bias, correction of retention and mortality 
should be investigated through sensitivity analysis using a range of plausible self-transfer and mor-
tality estimates. Lastly, tracing studies used heterogeneous approaches to reporting outcomes that 
may influence the comparability of findings reported.   
 
This review reported tracing a large number of LTFU patients in both rural and urban ART 
programmes in 12 sub-Saharan African countries, 11 of which are regarded as high HIV prevalence 
countries (WHO 2013). The vast majority of studies reported on public sector cohorts.  These find-
ings may therefore be representative of high prevalence public sector sub-Saharan African cohorts, 
but may not be directly generalizable beyond this setting. 
 
These findings confirm the value of tracing patients LTFU, both to ensure appropriate care is 
provided for the individual and to improve the accuracy of outcome reporting for the overall pro-
gramme. Due to heterogeneous programmes and contexts, retention and mortality should ideally be 
reported after tracing all or a random sample of LTFU patients. Where this is not feasible, retention 
and mortality estimates need to be adjusted to account for self-transferred patients and unreported 
deaths. The estimates provided by this study can be used to inform outcomes amongst patients rec-
orded as LTFU in sub-Saharan Africa. 
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In addition, these findings emphasise the importance of health systems accounting for pa-
tient mobility and transfer as a normal and expected evolution in ART scale-up.  Transfers need to be 
easily accounted for by monitoring systems so that self-transfers are not counted as LTFU.  This 
could be achieved by encouraging the use of unique patient identifiers that allow tracking of patients 
across facilities through standardized integrated monitoring systems (Harries et al. 2010, Fox et al. 
2012). Such systems are unfortunately not perfect and mechanisms need to be put in place to en-
sure patients are not issued with a new unique identifier at the new facility (McGuire et al. 2010).  
Alternative strategies could include strengthening referral systems and ensuring a regular exchange 
of information between facilities (Egger et al. 2011). As the number of sites providing ART increases, 
patient mobility is likely to become more common and should be supported by increasing patient 
awareness and understanding of transfer procedures (Mben et al. 2012), removing any pre-
conditions for transfer (Wubshet et al. 2013), simplifying facility processes for transfer (Miller et al. 
2010) and providing incentives in the form of a longer supply of ART. Longer ART supply also helps 
cover the period of moving between facilities thereby limiting unnecessary treatment interruptions 
(Grimsrud et al. 2013, Tweya et al. 2013). Health authorities should encourage facilities to be “trans-
fer friendly” so that patients feel comfortable with communicating their intention to transfer.  
 
This systematic review provides several directions for future research. ART programmes 
should continue to publish tracing studies undertaken as these provide valuable data to inform fu-
ture updated systematic reviews and meta-analysis. In particular, tracing studies are required from 
LMICs beyond sub-Saharan Africa and with study periods after 2010, to further assess whether self-
transfers increase and unreported deaths decrease with growing ART access and coverage.  Future 
reviews would be less prone to bias and provide a better quality of evidence if tracing studies fol-
lowed a standardized approach to reporting outcomes. It is particularly important to report on out-
comes of LTFU patients rather than cases traced and not only on deaths ascertained but patients 
who self-transfer, stop ART and return to care before and after tracing. Tracing studies should fur-
ther aim to ascertain the reasons for a patient self-transferring care. Patients who have stopped ART 
should be asked if they initially intended transferring their care and which obstacles prevented such 
transfer. This would allow assessment of obstacles to transfer notification and their impact on conti-
nuity of care.  Lastly, studies describing appropriate retention adjustment models are necessary to 
provide guidance to those reporting ART cohort outcomes in the future. 
 
 
 
In conclusion, ART programmes with high LTFU rates can expect large numbers of self-
transfers ‘hidden’ in the LTFU classification. To protect against inappropriate disinvestment from, 
and poor forecasting for, ART care provision, retention estimates need to be adjusted to account for 
self-transfers.  
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Table 1: Characteristics of included studies and cohorts 
N
o
. 
First 
author/ 
Year 
Study 
peri-
od 
Loca-
tion 
Set-
ting 
Sec
tor 
Study 
popu-
lation 
age 
No. 
site
s in 
co-
hor
t 
LTFU defi-
nition for 
tracing 
purposes 
Tracing 
method 
No. 
start 
ART 
in 
stud
y co-
co-
hort 
No
.  
LTF
U 
(%)
No. 
in 
trac
ing 
stu
dy 
(%) 
1 Alamo 
et al 
2012b 
 
2001-
2010 
Kam-
pala, 
Ugan-
da 
Ur-
ban 
NG
O 
Adult 1 Missed ap-
pointment 
>3 months 
2 home 
visits 
2713
* 
15
02
* 
(55
.4)
164
□
(10.
9)
2 Bisson  
et al 
2008 
2003 
 
Gabo-
rone, 
Bot-
swana 
 
Ur-
ban 
 
Pub
lic 
 
Adult 
 
1 Missed ap-
pointment 
> 1 month 
 
3 tele-
phone 
call at-
tempts, 
if unsuc-
cessful 
home 
visit 
410 
 
68
(16
.6)
68
(10
0)
3 Caluwa
erts et 
al   
2009 
2002-
2007 
Tete, 
Moza
mbiqu
e 
Ur-
ban 
Pub
lic  
Adult/ 
Paedi-
atric 
1 Missed ap-
pointment 
>2 months 
If volun-
teer 
knew 
out-
come 
record-
ed, oth-
erwise 
home 
visit 
2818 59
4
(21
.1)
594
(10
0)
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4 Chima 
& 
Lupond
wana 
2011 
2008-
2009 
Vry-
heid, 
South 
Africa 
Ur-
ban 
Pub
lic 
Mixed 1 Missed ap-
pointment 
 
Tele-
phone 
calls and 
home 
visits 
 
NR 34
3
343
(10
0)
5 Dahab 
et al 
2011 
2005-
2007 
Gaut-
eng &  
North
west,  
South 
Africa 
Ru-
ral 
& 
Ur-
ban 
Pub
lic 
& 
Pri-
vat
e  
Adult 2 Missed 6m 
appoint-
ment >1 
month 
3 at-
tempts 
made to 
trace 
patient  
(meth-
ods NR) 
411 95
(23
.1)
95
(10
0)
6 Dalal et 
al 2008 
2004-
2005 
Jo-
hanne
sburg, 
South 
Africa 
Ur-
ban 
Pub
lic  
Adult 1 Missed ap-
pointment 
> 6 weeks 
Tele-
phone 
calls, if 
unsuc-
cessful 
home 
visit  
1631 26
7
(16
.4)
267
(10
0)
7 Deribe 
et al 
2008 
2005-
2007 
Jimma
, Ethi-
opia 
Ur-
ban 
Pub
lic 
Adult 1 Missed >2 
appoint-
ments 
Tele-
phone 
calls and 
home 
visits 
1796 16
1
(9.
0)
173
(10
0)
8 Geng at 
al 2011 
2006-
2007 
Mbara
ra, 
Ugan-
da 
Ru-
ral 
Pub
lic  
Adult  1 No visit > 6 
months 
Home 
visit  
3628 82
9
(22
.9)
128
□
(15.
4)
9 ⌂ 
Gungu
wo et al  
2012 
2010 Bula-
wayo, 
Zim-
babwe 
Ur-
ban 
Pub
lic 
Adult◊ 1 No visit > 3 
months 
Home 
visit  
1796
◊ 
16
1
(9.
0)
161
(10
0)
1
0 
⌂ Kato 
et al 
2013 
2010 Mumb
wa 
dis-
trict, 
Zam-
bia 
Ru-
ral  
Pub
lic 
NR > 2 
 
Not de-
fined 
Home 
visit  
352∆ 53
(15
.1)
53
(10
0)
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1
1 
Krebs 
et al 
2008 
2005 Lusa-
ka, 
Zam-
bia 
Ur-
ban 
Pub
lic 
 
NR 12 Missed ap-
pointment 
1 week to 1 
month (fa-
cility de-
pendent) 
Tele-
phone 
calls and 
home 
visits  
 
1619
8 
34
08 
(21
.0)
654
(19.
2)
1
2 
Maske
w et al 
2007 
2006-
2007 
Jo-
hanne
sburg, 
South 
Africa 
Ur-
ban 
Pub
lic  
NR 1 Missed ap-
pointment 
> 1 month 
Tele-
phone 
call 
5821 15
4
(2.
7)
154
(10
0)
1
3 
Mben 
et al  
2012 
2006-
2007 
Ya-
ounde, 
Came-
roon 
Ur-
ban 
Pub
lic 
NR 1 Missed ap-
pointment 
> 1 month 
3 at-
tempts 
made to 
trace 
patient 
(meth-
ods NR) 
 NR NR NR
1
4 
McGuir
e et al 
2010  
2004-
2007 
Chirad
zulu, 
Mala-
wi 
Ru-
ral 
Pub
lic  
Adult/ 
Paedi-
atric¥  
11 Missed ap-
pointment 
> 1 month 
1-3 
home 
visits 
1063
3◊ 
11
86
(11
.2)
118
6
(10
0)
1
5 
Miller 
et al 
2010 
2008-
2009 
Lim-
popo 
and 
Gaut-
eng, 
South 
Africa 
Ru-
ral 
& 
Ur-
ban 
Pub
lic 
Adult 2 Missed ap-
pointment 
> 1 month 
Tele-
phone 
calls, if 
unsuc-
cessful 
home 
visit  
528 40
(7.
6)
40
(10
0)
1
6 
Muteve
dzi et al  
2013 
2004-
2012 
Hlabis
a, 
South 
Africa 
Ru-
ral 
Pub
lic  
Adult 17 No visit >6 
months 
Tele-
phone 
calls and 
home 
visits∩  
4674 55
8
(11
.9)
558
(10
0)
1
7 
O’Conn
or et al  
2011 
2007-
2009 
Jo-
hanne
sburg, 
South 
Africa 
Ur-
ban 
Pub
lic  
NR 4 Missed ap-
pointment 
at down re-
ferral site > 
6 weeks 
3 tele-
phone 
call at-
tempts, 
if unsuc-
cessful 
home 
3336 49
0
(14
.7)
490
(10
0)
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visit 
1
8 
⌂ 
Omotos
o et al  
2011  
2008-
2010 
Ada-
mawa 
state, 
Nige-
ria 
Ru-
ral 
Pub
lic  
NR 5 Missed ap-
pointment 
> 3 months 
Home 
visit  
2350
∏ 
38
0
(16
.2)
185
(48.
7)
1
9 
Onoka 
et al 
2012 
2007 Enugu 
state, 
Nige-
ria 
Ru-
ral 
& 
Ur-
ban 
Pub
lic 
& 
Pri-
vat
e 
NR 2 Missed 3 
appoint-
ments 
Tele-
phone 
calls and 
home 
visits 
1034 21
9
(21
.2)
219
(10
0)
2
0 
Peltzer 
et al   
2011 
2007-
2008 
Uthuk
ela 
dis-
trict, 
South 
Africa 
Ru-
ral 
& 
Ur-
ban 
Pub
lic 
Adult 3 Missed 2 
consecu-
tive or 
6/12m ap-
pointment 
5 tele-
phone 
call at-
tempts, 
if unsuc-
cessful 
up to 3 
home 
visits 
727 16
9
(23
.3)
169
(10
0)
2
1 
Rosen 
& 
Ketlhap
ile 2010 
2004-
2009 
Jo-
hanne
sburg, 
South 
Africa 
Ur-
ban 
Pub
lic  
Adult 1 Missed ap-
pointment 
> 1 month 
1-8 Tel-
ephone 
calls 
1167
8 
86
9
(7.
4)
493
□
(56.
8)
2
2 
Saka et 
al 2013 
2008-
2011 
Togo Ru-
ral 
& 
Ur-
ban 
Pub
lic 
& 
Pri-
vat
e & 
NG
O 
Adult 28 No visit >4 
months 
 
Tele-
phone 
calls 
 
1661
7 
12
16 
(7.
3)
121
6
(10
0)
2
3 
⌂ Sie 
et al 
2011 
2010 Cote 
d'Iv-
oire 
Ru-
ral 
& 
Ur-
ban 
Pub
lic 
NR 12 Not de-
fined 
Tele-
phone 
calls 
NR 42
21
422
1
(10
0)
A
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2
4 
⌂ 
Toure 
et al 
2012  
2004-
2011 
Cote 
d'Iv-
oire 
Ru-
ral 
& 
Ur-
ban Pub
lic  
NR 138 No visit > 3 
months 
Tele-
phone 
calls 
4785
8 
11
05
1
(23
.1)
110
51
(10
0)
2
5 
Tweya 
et al 
2013 
2006-
2010 
Li-
longw
e, Ma-
lawi 
Ru-
ral 
& 
Ur-
ban 
Pub
lic  
Adult 2 Missed ap-
pointment 
> 3 weeks 
Tele-
phone 
calls and 
home 
visits  
2137
0 
35
10ⱡ 
(16
.4)
351
0
(10
0)
2
6 
Weigel 
et al 
2011 
2002-
2005 
Li-
longw
e, Ma-
lawi 
Ru-
ral 
& 
Ur-
ban 
Pub
lic  
Adult/ 
Paedi-
atric 
1 Missed ap-
pointment 
> 2 weeks 
Up to 3 
at-
tempts. 
Tele-
phone 
calls and 
home 
visits  
3846 18
40
(47
.8)
180
0
(97.
8)
2
7 
Wubsh
et et al 
2013 
2005-
2010 
Gon-
dar, 
Ethio-
pia 
Ru-
ral  
Pub
lic  
Adult 1 Missed ap-
pointment 
> 3 months 
Home 
visits 
3012 55
1
(18
.3)
551
(10
0)
2
8 
Yu  
2007 
2005-
2006 
North
ern 
Mala-
wi 
Ru-
ral 
& 
Ur-
ban 
Pub
lic  
Adult/ 
Paedi-
atric 
4 No visit for 
> 3 months 
Home 
visits 
5009 25
3
(5.
1)
253
(10
0)
⌂ conference abstract 
NR = not reported 
*Disaggregated ART data from (Alamo et al. 2012)
□ random sample of LTFU paƟents  
◊ Corresponding author provided data not re-
ported in publication/conference abstract (see 
acknowledgements) 
∆ Data from conference poster download at-
tached to conference abstract 
¥ Disaggregated adult data reported for prima-
ry and secondary outcomes 
∏ Abstract does not state whether ART/pre-
ART cohort.  Unable to contact author.  As-
sumed ART cohort. 
∩ Surveillance database maintained by semi-
annual household survey (Bor et al. 2013) 
ⱡ LTFU patients less 613 formal transfers 
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Table 2: True outcomes of LTFU patients traced 
N
o.
  
First au-
thor 
No. in  
tracing 
study 
No. 
traced 
(%)
No. self- 
transfers 
(%)
ⱡNo. still at 
same ART 
facility (%)
No. 
stopped 
care (%)
No. 
alive 
(%) 
No. 
died 
(%)
1 Alamo  164 158
(96.3)
86
(54.4)
  56
(35.4)
142 
(89.9) 
16
(10.1)
2 Bisson  
 
68 
 
46 
(67.7)
NR 6 
(13.0) 
40
(87.0)
3 Caluwaert
s  
594 214
(36.0)
43
(20.1)
7
(3.3)
46
(21.5)
96 
(44.9) 
118
(55.1)
4 Chima  343 
 
251 
(73.2)
NR  120  
(47.8) 
131 
(52.2)
5 Dahab  95 67
(70.5)
3
(4.5)
  40
(59.7)
43 
(64.2) 
24
(35.8)
6 Dalal  267 173
(64.8)
30
(17.3)
  60□
(34.7)
90 
(52.0) 
83
(48.0)
7 Deribe  173 108
(62.4)
19
(17.6)
  89□
(82.4)
108 
(100) 
NR○
8 Geng  128 111
(86.7)
35*
(31.5)
  13*
(11.7)
79 
(71.2) 
32
(28.8)
9 Gunguwo  161 111
(68.9)
6
(5.4)
16
(14.4)
11
(9.9)
33 
(29.7) 
78
(70.3)
1
0 
Kato 53 48
(90.6)
10
(20.8)
 8 
(16.7)
15
(31.3)
33 
(68.8) 
15
(31.3)
1
1 
Krebs  
 
654 
 
417 
(63.8)
NR  225  
(54.0) 
192  
(46.0)
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1
2 
Maskew  154 70
(45.5)
10
(14.3)
  41□
(58.6)
51 
(72.9) 
19
(27.1)
1
3 
Mben  NR 231 22
(9.5)
  111□
(48.1)
133 
(57.6) 
98
(42.4)
1
4 
McGuire  1186 344
(29.0)
63
(18.3)
  48□
(14.0)
111 
(32.3) 
233
(67.7)
1
5 
Miller  40 38
(95.0)
16
(42.1)
 2
(5.3)
13∆
(34.2)
31 
(81.6) 
7
(18.4)
1
6 
Mutevedz
i  
 
558 
 
394
(70.6)
NR
303  
(76.9) 
91
(23.1)
1
7 
O'Connor  490 374
(76.3)
71
(19.0)
281
(75.1)
15
(4.0)
367 
(98.1) 
7
(1.9)
1
8 
Omotoso 185 151
(81.6)
10
(6.6)
  27 ξ ∆
(17.9)
132∏ 
(87.4) 
19
(12.6)
1
9 
Onoka  219 100
(45.7)
15
(15.0)
4
(4.0)
30∆
(30.0)
49 
(49.0) 
51
(51.0)
2
0 
Peltzer  169 147
(87.0)
58
(39.5)
  7
(4.8)
65 
(44.2) 
82
(55.8)
2
1 
Rosen  493 260
(52.7)
79
(30.4)
56
(22.0)
70
(26.9)
205 
(78.9) 
55
(21.2)
2
2 
Saka  
 
1216 
 
202
(16.6)
NR  NR 114  
(56.4) 
88
(43.6)
2
3 
Sie  4221 1038
(24.6)
77
(7.4)
  NR 907 
(87.4) 
131
(12.6)
2
4 
Toure  11051 2294
(20.8)
200
(8.7)
  NR 2104 
(91.7) 
190
(8.3)
2
5 
Tweya  3510◊ 2254 121  ¥ 1302 952
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(64.2) (5.4) (57.8) (42.2)
2
6 
Weigel  1800 534
(29.7)
128
(24.0)
 157
(29.4)
32
(6.0)
317 
(59.4) 
217
(40.6)
2
7 
Wubshet  551 486
(88.2)
118
(24.3)
  135
(27.8)
253 
(52.1) 
233
(47.9)
2
8 
Yu  253 185
(73.1)
20
(10.8)
1
(0.5)
37
(20.0)
58 
(31.4) 
127
(68.7)
ⱡ Upon tracing found patients still receiving ART 
at the same facility. Patient records either in-
correct or patients returned to care between 
LTFU classification and tracing. 
□ No. of paƟents who stopped ART not report-
ed.  Ascertained from % breakdown of reasons 
provided for stopping ART. 
○ Author confirmed that deaths determined 
upon tracing were included in those not traced 
(not in reported deaths).  
* Only directly interviewed 48/79 patients 
found alive. True outcomes for remaining 31 
patients unknown.  
∆ Patients who upon interviewing refused 
to answer/denied their HIV status have 
been added to those reported to have 
stopped ART. 
ξ patients reported to have returned to 
care after tracing not included 
∏ reported alive categories add up to 139 
(more than those traced less died).  As-
sumed alive = traced less deaths. 
◊ Study reports cases traced not patients. 
Corresponding author provided data not 
reported (see acknowledgements). 
¥ LTFU cases not patients that stopped 
ART reported.  
NR = not reported 
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58 full text articles as-
sessed for eligibility  
2597 records identified through 
database searching 
1365 records after du-
plicates removed 
380 records after titles 
screened 
36 studies selected 
23 studies included in self-transfer meta-analysis 
27 studies included in the unreported mortality meta-analysis    
1235 excluded dupli-
cates 
985 excluded  
after title screening
322 excluded  
after abstract
29 excluded after  
full text review:
3 records identi-
fied through refer-
ence lists 
364 records identified through 
other sources 
361 records iden-
tified from con-
ferences 
7 records after titles 
and abstracts simulta-
neously assessed for 
eligibility
28 studies included in the systematic review  
Figure 1: Identification and selection of studies flow diagram 
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Figure 5:  Meta-regression 
 
 
 
 
 
